Wedbush assumed coverage on shares of Kura Oncology (NASDAQ:KURA) in a research note issued on Wednesday, December 20th, MarketBeat reports. The brokerage set an “outperform” rating and a $19.00 price target on the stock. Wedbush’s price target would suggest a potential upside of 21.41% from the company’s current price.
Several other equities analysts also recently commented on the stock. Oppenheimer set a $18.00 target price on shares of Kura Oncology and gave the stock a “buy” rating in a report on Monday, December 11th. Cann reissued a “buy” rating and issued a $17.50 target price on shares of Kura Oncology in a report on Monday, December 11th. BidaskClub cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Thursday, December 7th. ValuEngine cut shares of Kura Oncology from a “hold” rating to a “sell” rating in a research report on Friday, December 1st. Finally, Citigroup boosted their price target on shares of Kura Oncology from $15.00 to $19.00 and gave the stock a “buy” rating in a research report on Thursday, November 9th. Three investment analysts have rated the stock with a sell rating and six have issued a buy rating to the company. Kura Oncology has a consensus rating of “Hold” and a consensus target price of $18.08.
Kura Oncology (KURA) opened at $15.65 on Wednesday. Kura Oncology has a 1-year low of $5.78 and a 1-year high of $17.50. The company has a debt-to-equity ratio of 0.07, a current ratio of 13.48 and a quick ratio of 13.48. The company has a market cap of $472.87 and a price-to-earnings ratio of -10.10.
Kura Oncology (NASDAQ:KURA) last released its earnings results on Tuesday, November 7th. The company reported ($0.38) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.01). research analysts expect that Kura Oncology will post -1.52 EPS for the current fiscal year.
A number of hedge funds have recently bought and sold shares of KURA. Candriam Luxembourg S.C.A. bought a new position in Kura Oncology during the third quarter valued at $8,073,000. EAM Investors LLC bought a new position in Kura Oncology during the third quarter valued at $2,884,000. State Street Corp bought a new position in Kura Oncology during the second quarter valued at $1,394,000. Northern Trust Corp increased its position in Kura Oncology by 939.3% during the second quarter. Northern Trust Corp now owns 147,483 shares of the company’s stock valued at $1,372,000 after acquiring an additional 133,293 shares during the last quarter. Finally, Artal Group S.A. bought a new position in Kura Oncology during the third quarter valued at $1,495,000. Institutional investors and hedge funds own 64.26% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This piece was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of United States & international copyright legislation. The legal version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/kura-oncology-kura-coverage-initiated-by-analysts-at-wedbush.html.
About Kura Oncology
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
Receive News & Ratings for Kura Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology and related companies with MarketBeat.com's FREE daily email newsletter.